Phosphodiesterase 5 Inhibitors
"Phosphodiesterase 5 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
| Descriptor ID |
D058986
|
| MeSH Number(s) |
D27.505.519.389.735.500
|
| Concept/Terms |
Phosphodiesterase 5 Inhibitors- Phosphodiesterase 5 Inhibitors
- Inhibitors, Phosphodiesterase 5
- Phosphodiesterase Type 5 Inhibitors
- PDE-5 Inhibitors
- Inhibitors, PDE-5
- PDE 5 Inhibitors
- PDE5 Inhibitors
- Inhibitors, PDE5
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 5 Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 5 Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase 5 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 5 Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase 5 Inhibitors" by people in Profiles.
-
The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy. Urol Oncol. 2022 02; 40(2):57.e1-57.e7.
-
Precautions and Monitoring of Patients Taking Phosphodiesterase Type 5 Inhibitors Who are at Risk of Increased Intraocular Pressure. Drugs Aging. 2019 11; 36(11):991-997.
-
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. J Am Heart Assoc. 2019 01 08; 8(1):e011343.
-
Randomized Controlled Trial of a Leucine-Metformin-Sildenafil Combination (NS-0200) on Weight and Metabolic Parameters. Obesity (Silver Spring). 2019 01; 27(1):59-67.
-
Perioperative Sildenafil Therapy in Pediatric Congenital Cardiac Disease Patients. Int Heart J. 2018 Nov 28; 59(6):1333-1339.
-
Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. Drugs Aging. 2018 03; 35(3):175-187.
-
Mechanisms and Treatment of Halogen Inhalation-Induced Pulmonary and Systemic Injuries in Pregnant Mice. Hypertension. 2017 08; 70(2):390-400.
-
Off-Target Effect of Sildenafil on Postsurgical Erectile Dysfunction: Alternate Pathways and Localized Delivery System. J Sex Med. 2016 12; 13(12):1834-1843.
-
Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Dig Dis Sci. 2015 Nov; 60(11):3491-4.
-
Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. Curr Opin Cardiol. 2015 May; 30(3):250-8.